In prostate cancer, glioma, endometrial cancer, and breast cancer, the IL-6/gp130/STAT3 signaling pathway has been demonstrated to be involved in the regulation of CSC properties such as self-renewal, stemness marker expression, and tumor cell growth [22,23,24,25]. Here, IL6 is linked to prostate carcinoma.